AccessibilityHelp
MedMira logo

MedMira(OTC) MMIRF

Market Cap$27.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2012)-3%
5 Year-60%
1 Year-20%
1 Month+0%
$0.04
+148.75%
+0.02Today
MedMira last closing stock price
MetricPriceDate
Last closeUSD 0.042026-10-22
MedMira stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.042026-10-01
1 month+0%USD 0.042026-09-16
3 month-0.5%USD 0.042026-07-23
Year to date+231.67%USD 0.012025-12-31
1 year-20.4%USD 0.052025-10-22
3 year-43.14%USD 0.072023-10-13
5 year-60%USD 0.102021-10-22
Since inception-2.93%USD 0.042012-03-26

MedMira Financials at a Glance

Market Cap

$27.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$370.52K

Net Income (TTM)

-CA$2.71M

EPS (TTM)

-$0.00

P/E Ratio

-12.84

Dividend

$0.00

Beta (Volatility)

1.18 (Average)

Price

$0.04

Volume

2,000

Open

$0.04

Previous Close

$0.04

Daily Range

$0.04 - $0.04

52-Week Range

$0.00 - $0.95

Estimated Earnings Date

Jun 30, 2026

MMIRF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MedMira

MedMira Inc. is a biotechnology firm focused on the research, development, manufacturing, and distribution of rapid diagnostic solutions. The company operates globally, providing innovative testing products that cater to various healthcare needs.

Products and Services
  • Reveal HIV tests for HIV-1 and HIV-2 antibodies
  • Multiplo series for multiplex testing of multiple infections
  • VYRA CoV2 for SARS-CoV-2 antigen detection
Growth Outlook
  • Expansion into new markets is underway, enhancing global reach
  • Increased demand for rapid diagnostics amid ongoing health crises
  • Strategic partnerships are being formed to boost product distribution
Financial Highlights
  • Recent quarterly revenue of CAD 241,108 shows potential for growth
  • Trailing twelve months (TTM) revenue indicates a focus on recovery
  • Operating expenses remain high, reflecting ongoing investment in R&D
MedMira Inc. has established itself as a key player in the biotechnology sector, particularly in rapid diagnostics. The company's diverse product offerings, including tests for HIV, syphilis, and COVID-19, position it well to meet the growing demand for quick and reliable testing solutions. With a focus on expanding its market presence and forming strategic partnerships, MedMira is poised for potential growth in the coming years. Financially, the company has faced challenges, as indicated by its recent quarterly revenue and high operating expenses. However, the revenue figures suggest a foundation for recovery and growth. The ongoing investment in research and development is crucial for future product innovation and market competitiveness. Overall, MedMira Inc. presents an intriguing opportunity within the biotechnology landscape, particularly for those interested in the rapid diagnostics segment.
AI Generated • Oct 18, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

CEO

Hermes Hermes Chan

Website

www.medmira.com

Headquarters

Halifax, NS B3S 1B3, CA

MMIRF Financials

Key Financial Metrics (TTM)

Gross Margin

-448.07%

Operating Margin

-473.40%

Net Income Margin

-808.18%

Return on Equity

12.68%

Return on Capital

N/A

Return on Assets

-88.07%

Earnings Yield

-7.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$27.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

701.73M

Volume

2.00K

Avg. Volume

2.27K

Financials (TTM)

Gross Profit

-CA$238.70K

Operating Income

-CA$1.94M

EBITDA

-CA$1.64M

Operating Cash Flow

-CA$1.05M

Capital Expenditure

CA$4.00

Free Cash Flow

-CA$1.05M

Cash & ST Invst.

CA$0.00

Total Debt

CA$17.41M

MedMira Performance Analysis

MedMira annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-07-31CAD 750,206N/A
20232023-07-31CAD 322,349-57.0%
20242024-07-31CAD 303,564-5.8%
20252025-07-31CAD 172,448-43.2%
MedMira sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-14.3%
Q12025-10-317.0%
Q22026-01-31-54.7%
Q32026-04-30882.5%
MedMira annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-07-31CAD -0.00N/A
20232023-07-31CAD -0.0038.1%
20242024-07-31CAD -0.0020.7%
20252025-07-31CAD -0.0034.3%
MedMira sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-07-31-10.0%
Q12025-10-319.1%
Q22026-01-31N/A
Q32026-04-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

CA$241.11K

+307.8%

Gross Profit

-CA$64.24K

-249.4%

Gross Margin

-26.64%

N/A

Market Cap

$27.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$537.09K

N/A

Employees

52

N/A

Net Income

-CA$483.50K

+50.8%

EBITDA

-CA$186.99K

+71.2%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Total Cash

CA$0.00

-100.0%

Total Debt

CA$17.41M

+71.3%

Accounts Receivable

CA$1.30M

-1.2%

Inventory

CA$191.68K

-14.8%

Long Term Debt

CA$2.52M

-29.8%

Short Term Debt

CA$14.90M

+126.7%

Return on Assets

-88.07%

N/A

Return on Invested Capital

7.98%

N/A

Free Cash Flow

-CA$150.58K

+83.6%

Operating Cash Flow

-CA$150.58K

+83.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MBX.TOMicrobix Biosystems Inc.
CA$0.32-1.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$90.50+8.30%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$47.98-8.54%
INTCIntel
$90.47+4.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$68.43+3.23%

Questions About MMIRF

What is the current price of MedMira?

MedMira is trading at $0.04 per share.

What is the 52-week range for MedMira?

Over the past 52 weeks, MedMira has traded between $0.00 and $0.95.

How much debt does MedMira have?

As of the most recent reporting period, MedMira reported total debt of CA$12.80M.

How much cash does MedMira have on hand?

MedMira reported CA$0.00 in cash and cash equivalents in its most recent financial results.

What is MedMira’s dividend yield?

MedMira does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services